Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Rhea-AI Summary

Harrow (Nasdaq: HROW) intends to offer an additional $50.0 million aggregate principal of its 8.625% senior unsecured notes due 2030 as an add-on to the existing $250.0 million series issued Sept 12, 2025.

Proceeds are planned for general corporate purposes, including product launches, development, and strategic opportunities; the offering targets qualified institutional buyers and non-U.S. persons under Regulation S.

Positive

• $50.0 million incremental debt to fund growth initiatives
• New notes join existing $250.0 million series, preserving same terms
• Proceeds earmarked for product development and strategic opportunities

Negative

• Adds leverage via an additional $50.0 million 8.625% senior unsecured note issuance
• Coupon of 8.625% increases interest expense burden versus lower-cost financing
• Offering restricted to QIBs/Reg S, limiting investor base and liquidity

News Market Reaction – HROW

+3.53%

3 alerts

+3.53% Session close to close

$1.32B Market Cap

0.1x Rel. Volume

In the Mar 24 session, HROW gained 3.53%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Harrow’s capital structure with an additional $50.0M of 8.625% senior unse...

Analysis

This announcement extends Harrow’s capital structure with an additional $50.0M of 8.625% senior unsecured notes due 2030, fungible with the prior $250.0M issue. The proceeds are earmarked for general corporate purposes, including growth initiatives. Historically, similar offerings generated mixed share reactions, so investors may watch how efficiently these funds translate into revenue growth and margin expansion relative to the notes’ interest burden.

Key Figures

Add-on notes size: $50.0M Coupon rate: 8.625% Existing 2030 notes: $250,000,000 +1 more

4 metrics

Add-on notes size $50.0M Additional 8.625% senior unsecured notes due 2030

Coupon rate 8.625% Interest rate on 2030 senior unsecured notes

Existing 2030 notes $250,000,000 Aggregate principal amount issued September 12, 2025

Notes maturity 2030 Maturity year of senior unsecured notes

Previous Offering Reports

2 past events · Latest: Sep 08 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 08	Notes pricing	Positive	-1.2%	Pricing of $250M 8.625% senior unsecured notes due 2030.
Sep 08	Notes offering launch	Positive	+7.5%	Launch of $250M 2030 notes and new $40M revolver facility.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past note offerings produced mixed reactions, with one modest decline and one notable gain, suggesting no consistent pattern to financing headlines.

Recent Company History

Recent history for Harrow shows active balance sheet management using 2030 senior unsecured notes. In September 2025, the company launched and then priced $250.0M of 8.625% notes due 2030, partly to refinance prior facilities and higher‑coupon notes. Those offerings saw one slightly negative (-1.18%) and one positive (+7.52%) next‑day move. Today’s add‑on offering extends that same financing structure to support additional corporate initiatives.

Key Terms

senior unsecured notes, aggregate principal amount, indenture, restricted subsidiaries, +3 more

7 terms

senior unsecured notes financial

"additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030"

Senior unsecured notes are a type of loan a company borrows from investors, promising to pay back with interest. They are called "unsecured" because they aren’t backed by specific assets like buildings or equipment, but "senior" because they are paid back before other debts if the company gets into trouble. Investors see them as a relatively safer way for companies to raise money.

aggregate principal amount financial

"an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes"

The aggregate principal amount is the total amount of money borrowed through a bond or loan that the borrower promises to repay. It’s like the original price tag on a loan or bond, showing how much money is involved in the deal. This number matters because it indicates the size of the debt and helps investors understand the scale of the borrowing.

indenture financial

"issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount"

An indenture is a legal agreement between a company that borrows money by issuing bonds and the people who buy those bonds. It explains the rules the company must follow, like paying back the money and keeping certain financial promises. This document helps both sides understand their rights and responsibilities.

restricted subsidiaries financial

"wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees"

Restricted subsidiaries are parts of a company that are legally limited by its loan or bond agreements from doing things like sending cash up to the parent, selling assets, taking on more debt, or changing their business without permission. Investors care because these limits affect how easily the parent company can use that unit’s money or collateral — like rooms in a house that are locked and unavailable when you need cash or want to refinance — which changes credit risk and financial flexibility.

qualified institutional buyers financial

"offered only to persons reasonably believed to be “qualified institutional buyers,” as that term is defined"

Qualified institutional buyers are large organizations, like big investment firms or banks, that are allowed to buy certain types of investment opportunities not available to everyday investors. Their size and experience matter because it ensures they understand and can handle complex financial deals, making markets more efficient and secure.

Rule 144A regulatory

"qualified institutional buyers," as that term is defined under Rule 144A of the Securities Act"

Rule 144A is a regulation that makes it easier for companies to sell private bonds to large investors without going through all the usual rules that apply to public sales. It matters because it helps companies raise money more quickly and privately, often attracting big investors looking for special deals.

Regulation S regulatory

"outside the United States to non-“U.S. persons” in accordance with Regulation S under the Securities Act"

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company’s existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.

Harrow intends to use the net proceeds from this incremental issuance for general corporate purposes, which may include initiatives to accelerate growth (e.g., new product launches), funding upcoming product development activities, future strategic business development opportunities, and related investments.

The 2030 Notes and the related guarantees have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the 2030 Notes and the related guarantees are being offered only to persons reasonably believed to be “qualified institutional buyers,” as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-“U.S. persons” in accordance with Regulation S under the Securities Act.

A confidential offering memorandum for the Offering, dated as of today, is being made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including, without limitation, statements regarding the Offering and the expected use of proceeds therefrom. These statements are based on currently available operating, financial, economic and other information, and are subject to a number of significant risks and uncertainties. A variety of factors, many of which are beyond our control, could cause actual future results to differ materially from those projected in the forward-looking statements. Specific factors that might cause such a difference include, but are not limited to: changes in market conditions, negotiation of final transaction documents, changes in operations, business, financial or other conditions relevant to the planned transactions, and other execution risks related to the completion of the transactions described herein, as well as other risks detailed in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. We believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, we may not be able to complete the potential transactions on terms expected or at all, and our actual results may differ significantly from those expected or implied by our forward-looking statements. These and other risks are detailed in our filings with the Securities and Exchange Commission. We do not undertake any obligation to publicly update or revise these forward-looking statements after the date of this press release to reflect future events or circumstances, except as required by applicable law. We qualify any and all of our forward-looking statements by these cautionary factors.

Contact:

Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com 
617-913-8890

FAQ

What exactly is Harrow (HROW) offering on March 24, 2026?

Harrow is offering an additional $50.0 million aggregate principal of 8.625% senior unsecured notes due 2030. According to the company, these notes will be issued as an add-on to the existing $250.0 million series and share the same terms except issue date and price.

How will Harrow (HROW) use proceeds from the $50.0 million 2030 notes?

Proceeds will be used for general corporate purposes, including new product launches and development. According to the company, funds may also support strategic business development opportunities and related investments to accelerate growth.

Are the additional 2030 notes from Harrow (HROW) different from the Sept 12, 2025 issuance?

The additional notes will be treated as a single series with the existing notes and have the same terms except for issuance date and issue price. According to the company, they will be governed by the same indenture as the Existing Notes.

Who can buy Harrow's (HROW) additional 8.625% notes due 2030?

The offering is restricted to qualified institutional buyers and non-U.S. persons under Regulation S. According to the company, the 2030 Notes and guarantees are not registered under the Securities Act and rely on applicable exemptions.

What are investor risks tied to Harrow's (HROW) add-on note offering?

Risks include higher interest expense from an 8.625% coupon and increased leverage which may pressure cash flows. According to the company, the notes are senior unsecured and subject to existing and future guarantee structures, affecting creditor recovery profiles.

When were Harrow's (HROW) Original 2030 Notes issued and how does this offering relate?

The Existing 2030 Notes were issued on September 12, 2025; the March 24, 2026 add-on will be issued under the same indenture and treated as a single series. According to the company, only issue date and price will differ.